Literature DB >> 28211154

KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.

D Di Bona1, A Aiello2, C Colomba3, M Bilancia4, G Accardi2, R Rubino3, L Giannitrapani5, A Tuttolomondo5, A Cascio3, M F Caiaffa6, S Rizzo7, G Di Lorenzo5, G Candore2,7, G Duro8, L Macchia1, G Montalto5, C Caruso2,7.   

Abstract

Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIR and HLA loci are highly polymorphic, and certain HLA-KIR combinations have been found to protect against viral infections. In this study, we analysed whether the KIR/HLA repertoire may influence the course of hepatitis B virus (HBV) infection. Fifty-seven subjects with chronic hepatitis B (CHB), 44 subjects with resolved HBV infection and 60 healthy uninfected controls (HC) were genotyped for KIR and their HLA ligands. The frequency of the HLA-A-Bw4 ligand group was higher in CHB (58%) than subjects with resolved infection (23%) (crude OR, 4.67; P<.001) and HC (10%) (crude OR, 12.38; P<.001). Similar results were obtained for the HLA-C2 ligand group, more frequent in CHB (84%), than subjects with resolved infection (70%) (crude OR, 2.24; P<.10) and HC (60%) (crude OR, 3.56; P<.01). Conversely, the frequency of KIR2DL3 was lower in CHB (81%) than in subjects with resolved infection (98%) (crude OR, 0.10; P<.05). These results suggest a detrimental role of HLA-A-Bw4 and HLA-C2 groups, which are associated with the development of CHB, and a protective role of KIR2DL3. A stepwise variable selection procedure, based on multiple logistic regression analysis, identified these three predictive variables as the most relevant, featuring high specificity (90.9%) and positive predictive value (87.5%) for the development of CHB. Our results suggest that a combination of KIR/HLA gene/alleles is able to predict the outcome of HBV infection.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HLAzzm321990; zzm321990killer cell immunoglobulin-like receptorzzm321990; zzm321990natural killerzzm321990; hepatitis B virus

Mesh:

Substances:

Year:  2017        PMID: 28211154     DOI: 10.1111/jvh.12698

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

1.  The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans.

Authors:  Danilo Di Bona; Janardan P Pandey; Anna Aiello; Massimo Bilancia; Giuseppina Candore; Calogero Caruso; Claudia Colomba; Giovanni Duro; Mattia Emanuela Ligotti; Luigi Macchia; Sergio Rizzo; Giulia Accardi
Journal:  Immunology       Date:  2019-11-12       Impact factor: 7.397

2.  The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals.

Authors:  Alireza Shah-Hosseini; Mohammad Jafari; Asadollah Mohammadi; Roozbeh Sanaei; Seyed Moayed Alavian; Amin Doosti-Irani; Mehrnoush Nooradeh Keykavousi; Nader Tajik
Journal:  Med Microbiol Immunol       Date:  2017-10-14       Impact factor: 3.402

3.  Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Authors:  Neda Nemat-Gorgani; Hugo G Hilton; Brenna M Henn; Meng Lin; Christopher R Gignoux; Justin W Myrick; Cedric J Werely; Julie M Granka; Marlo Möller; Eileen G Hoal; Makoto Yawata; Nobuyo Yawata; Lies Boelen; Becca Asquith; Peter Parham; Paul J Norman
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

Review 4.  Natural killer cell education in human health and disease.

Authors:  Jeanette E Boudreau; Katharine C Hsu
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

5.  Association of Inhibitory Killer Cell Immunoglobulin-like Receptor Ligands With Higher Plasmodium falciparum Parasite Prevalence.

Authors:  Jean C Digitale; Perri C Callaway; Maureen Martin; George Nelson; Mathias Viard; John Rek; Emmanuel Arinaitwe; Grant Dorsey; Moses Kamya; Mary Carrington; Isabel Rodriguez-Barraquer; Margaret E Feeney
Journal:  J Infect Dis       Date:  2021-07-02       Impact factor: 5.226

6.  KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.

Authors:  Louis-Marie Yindom; Maimuna Mendy; Christopher Bodimeade; Caroline Chambion; Peter Aka; Hilton C Whittle; Sarah L Rowland-Jones; Robert Walton
Journal:  PLoS One       Date:  2017-11-17       Impact factor: 3.240

7.  Chinese woodchucks with different susceptibility to WHV infection differ in their genetic background exemplified by cytochrome B and MHC-DRB molecules.

Authors:  Bin Zhu; Zhenni Zhu; Junzhong Wang; Shunmei Huang; Fanghui Li; Lu Wang; Yanan Liu; Qi Yan; Shunchang Zhou; Mengji Lu; Dongliang Yang; Baoju Wang
Journal:  Virol J       Date:  2018-06-18       Impact factor: 4.099

8.  Insights into the Interplay between KIR Gene Frequencies and Chronic HBV Infection in Burkina Faso.

Authors:  Pegdwendé Abel Sorgho; Jeremy James Martinson; Florencia Wendkuuni Djigma; Albert Théophane Yonli; Bolni Marius Nagalo; Tegwinde Rebeca Compaore; Dorcas Obiri-Yeboah; Birama Diarra; Herman Karim Sombie; Arsène Wendpagnangdé Zongo; Abdoul Karim Ouattara; Serge Théophile R Soubeiga; Lassina Traore; Lewis R Roberts; Jacques Simpore
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

9.  Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy.

Authors:  Lara Herrera; Myriam Martin-Inaraja; Silvia Santos; Marta Inglés-Ferrándiz; Aida Azkarate; Miguel A Perez-Vaquero; Miguel A Vesga; Jose L Vicario; Bernat Soria; Carlos Solano; Raquel De Paz; Antonio Marcos; Cristina Ferreras; Antonio Perez-Martinez; Cristina Eguizabal
Journal:  Immunology       Date:  2021-12-02       Impact factor: 7.215

10.  KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B.

Authors:  Wenting Li; Xiaokun Shen; Binqing Fu; Chuang Guo; Yanyan Liu; Ying Ye; Rui Sun; Jiabin Li; Zhigang Tian; Haiming Wei
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.